Summary

ICON plc is a global leader in clinical research and healthcare intelligence, founded in Dublin, Ireland in 1990. As one of the world's largest contract research organizations (CROs), ICON provides comprehensive outsourced development services to pharmaceutical, biotechnology, and medical device companies worldwide. The company operates in 55 countries with approximately 41,900 employees, offering end-to-end solutions that span the entire product development lifecycle. ICON's service portfolio includes clinical research services, adaptive trials, biosimilars, commercialization and outcomes consulting, medical imaging, laboratory services, and strategic support for traditional and digital health technologies. The company specializes in therapeutic areas such as oncology, cardiovascular diseases, central nervous system disorders, rare diseases, and women's health. With its 2021 acquisition of PRA Health Sciences, ICON significantly expanded its capabilities and market position, becoming a dominant force in the global CRO industry. The company is publicly traded on NASDAQ under the ticker ICLR and reported $8.28 billion in revenue for 2024.

Job description

What You Will Do

Provide scientific and medical imaging expertise to Commercial Development, Operations, and project teams throughout the clinical trial lifecycle.
Serve as a scientific subject matter expert and trusted advisor for sponsors, supporting study design, protocol review, imaging endpoint strategy, and solution development.
Provide scientific leadership and strategic guidance for imaging components of clinical trials focused on MASH, obesity, diabetes, and other metabolic diseases.
Advise sponsors and internal teams on the application of imaging biomarkers, quantitative imaging methods, and emerging technologies relevant to metabolic disease research.
Review and provide scientific oversight for imaging charters, image review manuals, site-facing materials, sponsor deliverables, and study reports.
Ensure imaging methodologies, endpoints, and operational approaches are aligned with protocol objectives, regulatory expectations, and industry best practices.
Contribute to the advancement of imaging methodologies and endpoint strategies that support the assessment of metabolic disease progression, treatment response, and clinical outcomes.
Support business development activities by participating in client meetings, capabilities presentations, bid defense meetings, RFPs, RFIs, and proposal development.
Build and maintain strong relationships with sponsors and key stakeholders, providing scientific consultation throughout the sales and study execution process.
Represent ICON at scientific conferences, industry forums, and working groups through presentations, publications, and participation in imaging standardization initiatives.
Partner with Marketing and Commercial teams to communicate ICON's scientific differentiators and support thought leadership activities.
Provide scientific training, mentorship, and consultation to internal teams, fostering continued development of imaging expertise across the organization.
Collaborate with Product Development and Technology teams to define scientific requirements and support the enhancement of innovative imaging solutions and proprietary software platforms.
Stay informed of emerging scientific, clinical, and regulatory developments related to metabolic diseases and their associated imaging applications.
Travel domestically and internationally as required (approximately 10%).
Perform other duties as assigned.

Your Profile

PhD required in a relevant scientific or technical discipline, preferably Biomedical Engineering, Electrical Engineering, Medical Physics, Physics, Imaging Sciences, or a closely related quantitative imaging field.
Significant experience within the pharmaceutical, biotechnology, CRO, or clinical research industry supporting imaging components of clinical trials.
Direct experience supporting imaging studies and imaging biomarkers in MASH, obesity, diabetes, and other metabolic disease indications is required.
Deep understanding of imaging biomarker development, quantitative image analysis, imaging endpoint strategy, and clinical trial design.
Experience in applying advanced imaging technologies, image analysis methodologies, and emerging imaging techniques in metabolic disease research.
Demonstrated expertise in imaging modalities commonly utilized in metabolic disease clinical trials, including the assessment of liver fat, fibrosis, body composition, and related metabolic endpoints.
Experience supporting business development activities, including client interactions, scientific consultation, proposal development, and bid defense meetings.
Strong leadership and collaboration skills with the ability to influence and work effectively across global, cross-functional teams.
Excellent scientific communication, presentation, and stakeholder management capabilities.
Demonstrated ability to translate complex scientific concepts into practical, client-focused solutions.
Strong strategic thinking, problem-solving, and decision-making skills.
Commitment to quality, innovation, and delivering exceptional customer experiences.
US location strongly preferred; will consider applicants from Mexico City, Mexico, Ireland, or UK
Ability to travel (10%)

Requirements

PhD required in a relevant scientific or technical discipline, preferably Biomedical Engineering, Electrical Engineering, Medical Physics, Physics, Imaging Sciences, or a closely related quantitative imaging field.
Significant experience within the pharmaceutical, biotechnology, CRO, or clinical research industry supporting imaging components of clinical trials.
Direct experience supporting imaging studies and imaging biomarkers in MASH, obesity, diabetes, and other metabolic disease indications is required.
Deep understanding of imaging biomarker development, quantitative image analysis, imaging endpoint strategy, and clinical trial design.
Experience in applying advanced imaging technologies, image analysis methodologies, and emerging imaging techniques in metabolic disease research.
Demonstrated expertise in imaging modalities commonly utilized in metabolic disease clinical trials, including the assessment of liver fat, fibrosis, body composition, and related metabolic endpoints.
Experience supporting business development activities, including client interactions, scientific consultation, proposal development, and bid defense meetings.
Strong leadership and collaboration skills with the ability to influence and work effectively across global, cross-functional teams.
Excellent scientific communication, presentation, and stakeholder management capabilities.
Demonstrated ability to translate complex scientific concepts into practical, client-focused solutions.
Strong strategic thinking, problem-solving, and decision-making skills.
Commitment to quality, innovation, and delivering exceptional customer experiences.
US location strongly preferred; will consider applicants from Mexico City, Mexico, Ireland, or UK
Ability to travel (10%)

Benefits

Competitive base salary
Performance related incentives
Medical coverage
Dental coverage
Vision coverage
Retirement and pension plans
Life assurance
Disability coverage
Employee assistance programmes
Wellbeing resources
Learning and development opportunities

Company overview

ICON plc is a global leader in clinical research and healthcare intelligence, founded in Dublin, Ireland in 1990. As one of the world's largest contract research organizations (CROs), ICON provides comprehensive outsourced development services to pharmaceutical, biotechnology, and medical device companies worldwide. The company operates in 55 countries with approximately 41,900 employees, offering end-to-end solutions that span the entire product development lifecycle. ICON's service portfolio includes clinical research services, adaptive trials, biosimilars, commercialization and outcomes consulting, medical imaging, laboratory services, and strategic support for traditional and digital health technologies. The company specializes in therapeutic areas such as oncology, cardiovascular diseases, central nervous system disorders, rare diseases, and women's health. With its 2021 acquisition of PRA Health Sciences, ICON significantly expanded its capabilities and market position, becoming a dominant force in the global CRO industry. The company is publicly traded on NASDAQ under the ticker ICLR and reported $8.28 billion in revenue for 2024.